Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bravo or bravado? Teva, Active move baseline to make PhIII oral MS miss a hit

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries and Active Biotech both saw their share price drop sharply after they said that oral laquinimod missed the primary endpoint of a major study, BRAVO – the second pivotal Phase III trial testing the investigational immunomodulator in relapsing-remitting multiple sclerosis. The drug did not significantly reduce annualised relapse rate from baseline to two years over placebo, and yet Teva said an adjusted analysis shows the drug was successful in reducing relapse and that it still plans to submit regulatory applications in the US and EU in early 2012.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts